Adaptimmune Therapeutics plc
ADAP
$0.2583
-$0.0656-20.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 178.03M | 175.04M | 141.46M | 18.36M | 60.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.03M | 175.04M | 141.46M | 18.36M | 60.28M |
| Cost of Revenue | 149.13M | 143.17M | 146.65M | 136.17M | 126.51M |
| Gross Profit | 28.90M | 31.87M | -5.19M | -117.81M | -66.23M |
| SG&A Expenses | 88.66M | 69.63M | 64.51M | 65.50M | 60.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 237.79M | 212.79M | 211.16M | 201.67M | 186.90M |
| Operating Income | -59.76M | -37.75M | -69.70M | -183.31M | -126.62M |
| Income Before Tax | -67.24M | -43.29M | -71.42M | -162.17M | -112.54M |
| Income Tax Expenses | 3.58M | 1.23M | 1.08M | 1.24M | 1.34M |
| Earnings from Continuing Operations | -70.81 | -44.52 | -72.50 | -163.41 | -113.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.81M | -44.52M | -72.50M | -163.41M | -113.87M |
| EBIT | -59.76M | -37.75M | -69.70M | -183.31M | -126.62M |
| EBITDA | -48.53M | -26.49M | -58.37M | -172.49M | -116.78M |
| EPS Basic | -1.72 | -1.25 | -2.05 | -4.37 | -3.13 |
| Normalized Basic EPS | -0.15 | -0.11 | -0.19 | -0.51 | -0.35 |
| EPS Diluted | -2.03 | -1.44 | -2.24 | -4.40 | -3.16 |
| Normalized Diluted EPS | -0.15 | -0.11 | -0.19 | -0.51 | -0.35 |
| Average Basic Shares Outstanding | 1.01B | 980.34M | 950.88M | 879.99M | 803.34M |
| Average Diluted Shares Outstanding | 168.91M | 164.10M | 159.19M | 146.66M | 134.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
